| Mrs Linda Y Ellis, NP | |
|
3950 17th St, Suite A, Baker City, OR 97814-1300 | |
| (541) 523-1001 | |
| (541) 523-1152 |
| Full Name | Mrs Linda Y Ellis |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 3950 17th St, Baker City, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841288339 | NPI | - | NPPES |
| 383852 | Other | MEDICARE PART A | |
| 276275 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 097006942N1 (Oregon) | Primary |
| Entity Name | Rodney E. Orr, Md, P.c |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619997418 PECOS PAC ID: 5799772620 Enrollment ID: O20040430000480 |
News Archive
A new analysis led by the University of Pittsburgh Graduate School of Public Health offers insights for nonprofit hospitals in implementing community health improvement programs. In a special issue of the Journal of Health Care for the Poor and Underserved that focuses on the Affordable Care Act, a multidisciplinary team of Pitt researchers explore published research on existing community benefit programs at U.S. hospitals and explain how rigorous implementation of such programs could help hospitals both meet federal requirements and improve the health of the populations they serve.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
Americana Corporation is pleased to announce a strategic partnership with COMS Interactive, LLC (Clinical Outcomes Management Systems or COMS). The partnership supports an interface between Americana Corporation's AmeraCare products/services and the COMS Daylight IQ™ disease management software.
Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).
In a move that some fear could compromise care for Medicare recipients, the Obama administration is proposing to remove special protections that guarantee seniors access to a wide selection of three types of drugs.
› Verified 1 days ago
| Entity Name | Urgent Care Oregon Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790706190 PECOS PAC ID: 2668563750 Enrollment ID: O20070803000109 |
News Archive
A new analysis led by the University of Pittsburgh Graduate School of Public Health offers insights for nonprofit hospitals in implementing community health improvement programs. In a special issue of the Journal of Health Care for the Poor and Underserved that focuses on the Affordable Care Act, a multidisciplinary team of Pitt researchers explore published research on existing community benefit programs at U.S. hospitals and explain how rigorous implementation of such programs could help hospitals both meet federal requirements and improve the health of the populations they serve.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
Americana Corporation is pleased to announce a strategic partnership with COMS Interactive, LLC (Clinical Outcomes Management Systems or COMS). The partnership supports an interface between Americana Corporation's AmeraCare products/services and the COMS Daylight IQ™ disease management software.
Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).
In a move that some fear could compromise care for Medicare recipients, the Obama administration is proposing to remove special protections that guarantee seniors access to a wide selection of three types of drugs.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Linda Y Ellis, NP 190 E Bannock St, Boise, ID 83712-6241 Ph: (208) 381-2222 | Mrs Linda Y Ellis, NP 3950 17th St, Suite A, Baker City, OR 97814-1300 Ph: (541) 523-1001 |
News Archive
A new analysis led by the University of Pittsburgh Graduate School of Public Health offers insights for nonprofit hospitals in implementing community health improvement programs. In a special issue of the Journal of Health Care for the Poor and Underserved that focuses on the Affordable Care Act, a multidisciplinary team of Pitt researchers explore published research on existing community benefit programs at U.S. hospitals and explain how rigorous implementation of such programs could help hospitals both meet federal requirements and improve the health of the populations they serve.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
Americana Corporation is pleased to announce a strategic partnership with COMS Interactive, LLC (Clinical Outcomes Management Systems or COMS). The partnership supports an interface between Americana Corporation's AmeraCare products/services and the COMS Daylight IQ™ disease management software.
Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).
In a move that some fear could compromise care for Medicare recipients, the Obama administration is proposing to remove special protections that guarantee seniors access to a wide selection of three types of drugs.
› Verified 1 days ago
Colleen Bettilyen Davenport, PMHNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3425 13th St, Baker City, OR 97814 Phone: 541-523-7400 Fax: 253-584-1508 | |
Debbra Lynn Forrester, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 218 N Pine Street, Baker City, OR 97814 Phone: 541-742-5023 Fax: 541-742-7210 | |
Mr. Korey Vance Ham, MN, FNP-C, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1705 Main St Apt 801, Baker City, OR 97814 Phone: 541-403-1132 | |
Mrs. Deborah J Vencill, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3950 17th St, Suite A, Baker City, OR 97814 Phone: 541-523-1001 | |
Karen C Andruss, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3950 17th St, Suite A, Baker City, OR 97814 Phone: 541-523-1001 Fax: 541-523-1152 | |
Kara J Del Curto, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2021 Court Ave, Baker City, OR 97814 Phone: 541-239-5261 Fax: 541-239-5262 | |
Tory Michael Thornton, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3820 17th St, Baker City, OR 97814 Phone: 541-523-4465 Fax: 541-524-9032 |